research Real-World Effectiveness and Safety of Tofacitinib for Alopecia Areata: A Retrospective Cohort Study of 202 Patients
Tofacitinib is safe and effective for treating moderate-to-severe alopecia areata.
Search
for
Sort by
Research
870-900 / 1000+ results 
research Early Real-World Experience With Baricitinib in the Treatment of Severe Alopecia Areata
Baricitinib shows promise in treating severe hair loss.
research The Role of Janus Kinase Inhibitors in the Treatment of Alopecia Areata: A Systematic Review
Janus kinase inhibitors show promise for treating alopecia areata but need more research for confirmation.
research Systematic Review of Newer Agents for the Management of Alopecia Areata in Adults: Janus Kinase Inhibitors, Biologics and Phosphodiesterase-4 Inhibitors
New oral treatments for adult hair loss show promise, especially JAK inhibitors, with mild side effects.
research Janus Kinase Inhibitors: An Innovative Treatment for Alopecia Areata
New medicines that block a specific pathway are showing promise for treating severe hair loss but need more testing for safety and effectiveness.
research Treatment of Lichen Planopilaris With Janus Kinase Inhibitors
Janus kinase inhibitors may help treat lichen planopilaris.
research Efficacy and Adverse Effects of Oral Janus Kinase Inhibitor Use in Patients With Lichen Planopilaris: A Retrospective Case Series and Systematic Review
Oral Janus kinase inhibitors may be an effective treatment option for lichen planopilaris with some risk of increased cholesterol and liver enzyme levels.
research Patient Experience of Off-Label Janus Kinase Inhibitor Use for Alopecia Areata in a Cohort of 34 Patients From a Single UK Practitioner: Exploring Changing Trends in Healthcare Provision and Access to Drug Treatments
Patients with alopecia areata face challenges accessing Janus kinase inhibitors, but some see positive results.
research Olumiant (Baricitinib): A Newly Approved Janus Kinase Inhibitor for the Treatment of Alopecia Areata
Olumiant® (Baricitinib) is effective for treating hair loss from Alopecia Areata.
research In-Silico Screening of ATP-Competitive Inhibitory Activities of Phytochemicals Against Janus Kinase 3 and Its In-Vitro Evaluation
Poncirin is a promising inhibitor of Janus Kinase 3, potentially better than tofacitinib.
research Supplementary Material for: Janus Kinase Inhibitors for the Treatment of Severe Alopecia Areata: An Open-Label Comparative Study
Ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata.
research Oral Janus Kinase Inhibitors for the Treatment of Alopecia Areata: A Systematic Review and Meta-Analysis
Both tofacitinib and ruxolitinib are effective and tolerable for treating alopecia areata.
research Topical Ruxolitinib for the Treatment of Alopecia Universalis
Topical Ruxolitinib may safely treat severe hair loss.
research The Role of Oclacitinib in the Management of Ischemic Dermatopathy in Four Dogs
Oclacitinib effectively treated a skin condition in dogs that didn't respond to other immunosuppressants.
research Alopecia Areata and Tofacitinib: A Prospective Multicenter Study from a Saudi Population
Tofacitinib is effective and safe for treating severe hair loss in a Saudi population.
research Folliculitis Decalvans Responsive to Tofacitinib: A Case Series
Tofacitinib may effectively treat folliculitis decalvans.
research Acne Exacerbation After Tofacitinib Treatment for Alopecia Areata
Tofacitinib treatment for hair loss may worsen acne.
research What’s New in Hair Loss
New treatments for hair loss show promise, but require more research on long-term effects and proper dosing.
research Oral Baricitinib Restores Hair Loss in Alopecia Areata
Baricitinib, a medication taken by mouth, was effective in regrowing hair for people with severe hair loss.
research Recalcitrant Lichen Planopilaris Treated with Upadacitinib: A Case Series
Upadacitinib may effectively treat resistant lichen planopilaris.
research The Efficacy of Baricitinib as a Treatment Option for Alopecia in Terms of Promoting Hair Regrowth and Improving Patient Reported Outcomes
Baricitinib effectively promotes hair regrowth in severe alopecia with minimal side effects.
research Novel Investigational Drugs for Alopecia Areata and Future Perspectives
JAK inhibitors are safe and effective for treating moderate-to-severe alopecia areata.
research Treatment of Refractory Folliculitis Decalvans With the Topical JAK Inhibitor Tofacitinib
Topical tofacitinib helped a man with severe scalp condition after other treatments failed.
research Systemic Immunotherapies
Systemic immunotherapies are used for immune-related hair loss but not usually for genetic hair loss, unless the patient has both conditions.
research A Single-Center Retrospective Study Evaluating the Efficacy of Intravenous Methylprednisolone Pulse Therapy for 113 Patients With Alopecia Areata
Intravenous methylprednisolone helped over half of alopecia areata patients regrow hair, but many relapsed.
research EE325 Budget Impact of Baricitinib for Patients with Severe Alopecia Areata
Adding Baricitinib for severe alopecia areata will have a small impact on a health plan's budget.
research Acne Exacerbation After Tofacitinib Treatment for Alopecia Areata
Tofacitinib, a hair regrowth treatment, may worsen acne.
research Hair Today, Gone Tomorrow: Potential of Tofacitinib and Ruxolitinib in Treating Hair Loss
Two drugs, tofacitinib and ruxolitinib, may help regrow hair by activating hair follicles.
research Selectively Targeting JAK1 or JAK3 Pathway Is Sufficient to Reverse Alopecia Areata
Blocking JAK1 or JAK3 helps reverse hair loss in a mouse model of alopecia areata.
research Alopecias in Humans: Biology, Pathomechanisms, and Emerging Therapies
New treatments for hair loss are emerging as we better understand hair growth and its genetic causes.